Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: A randomized, placebo-controlled trial
Journal of Clinical Gastroenterology Aug 08, 2019
Schmulson MJ, Chiu-Ugalde J, Sáez-Ríos A, et al. - In patients with irritable bowel syndrome (IBS), a multifactorial disorder, researchers tested the safety and effectiveness of PB+S (pinaverium bromide 100 mg plus simethicone 300 mg). In this 12-week, randomized, double-blind, placebo-controlled study of PB+S vs placebo BID, IBS-Rome III patients with abdominal pain/discomfort for at least 2 days within the week prior to baseline assessment were involved. The study sample consisted of 285 patients received at least 1 dose of PB+S (n = 140) or placebo (n = 145). There was no difference in the overall improvement of symptoms between groups. However, in abdominal pain and bloating, PB+S was superior. IBS-C and IBS-M patients displayed the best improvement in the frequency of stool types with PB+S. In IBS Quality of Life scores and adverse events, no differences were observed.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries